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A randomised, controlled trial of the effects of a mobile telehealth intervention on clinical and patient-
reported outcomes in people with poorly controlled diabetes  




The objective of this research is to determine the effects of mobile telehealth (MTH) on glycosylated 
haemoglobin (HbA1c) and other clinical and patient-reported outcomes in insulin-requiring people 
with diabetes. 
Methods 
A nine-month randomised, controlled trial compared standard care to standard care supplemented 
with MTH (self-monitoring, mobile-phone data transmissions, graphical and nurse-initiated feedback, 
and educational calls). Clinical (HbA1c, blood pressure, daily insulin dose, diabetes outpatient 
appointments (DOAs)) and questionnaire data (health-related quality of life, depression, anxiety) were 
collected. Mean group changes over time were compared using hierarchical linear models and Mann-
Whitney tests. 
Results 
Eighty-one paƌtiĐipaŶts ǁith a ďaseliŶe HďAϭĐ of ϴ.ϵϴ% ± ϭ.ϴϮ ǁeƌe ƌaŶdoŵised to the iŶteƌǀeŶtioŶ 
;Ŷ = ϰϱͿ aŶd staŶdaƌd Đaƌe ;Ŷ = ϯϲͿ. The Gƌoup ďǇ Tiŵe effeĐt ƌeǀealed MTH did Ŷot sigŶifiĐaŶtlǇ 
iŶflueŶĐe HďAϭĐ ;p = Ϭ.ϮϮϴͿ, ďut p ǀalues ǁeƌe ďoƌdeƌliŶe sigŶifiĐaŶt foƌ ďlood pƌessuƌe ;p = Ϭ.ϬϱϰͿ aŶd 
mental-health ƌelated ƋualitǇ of life ;p = Ϭ.ϬϱϳͿ. EǆaŵiŶatioŶ of effeĐt sizes aŶd ϵϱ% ĐoŶfideŶĐe 
intervals for mean group differences at nine months supported the existence of a protective effect of 
MTH on mental health-related quality of life as well as depression. None of the other measured 
outcomes were found to be affected by the MTH intervention. 
Conclusions 
Findings from this study must be interpreted with caution given the small sample size, but they do not 
support the widespread adoption of MTH to achieve clinically significant changes in HbA1c. MTH may, 
however, have positive effects on blood pressure and protective effects on some aspects of mental 
health. 




Telehealth (TH) encompasses a range of electronic applications used to exchange medical information 
fƌoŵ oŶe site to aŶotheƌ to iŵpƌoǀe health Đaƌe deliǀeƌǇ aŶd patieŶts͛ ĐliŶiĐal status.[1,2] The subset 
of telehealth applications focused on in this paper is the recording of clinical and self-management 
data and their transmission to health care providers for review and feedback (also referred to as 
telemonitoring). These make possible the tracking of self-monitoring data and receipt of personalised 
feedback, potentially facilitating pattern analysis, reinforcing health behaviours, and promoting goal-
setting, action planning or problem-solving.[3–8] Many of these TH applications are now available for 
use oŶ patieŶts͛ ŵoďile-phones.[9] The added value of mobile TH (MTH) is that the recording, 
transmission and receipt of feedback can happen in any place, at any time and from a personal device 
alƌeadǇ iŶtegƌated iŶto peoples͛ liǀes. Although Ŷot all ŵoďile appliĐatioŶs iŶĐlude featuƌes 
recommended in clinical guidelines[9] or have been approved by a regulatory authority,[10] they have 
the potential to support timely medical management (e.g. medication dosage review) as well as self-
management tasks related to lifestyle (e.g. physical activity, diet), medication taking (e.g. reminders), 
and self-monitoring (blood glucose (BG), blood pressure (BP)).[11] 
Recent reviews[12,13] have found an evidence-base to support the use of TH (mobile and non-
mobile) to improve glycaemic control (HbA1c). Pooled reductions in HbA1c following TH are 
sometimes, but not always, statistically significant and range between 0.03% and 0.51%.[14–22] The 
majority of reductions are small in magnitude (<0.4%); their clinical significance remains debatable. 
A limitation of TH studies underlined in several reviews[18,23] is that little attention has been given to 
other outcomes than HbA1c. HbA1c is the gold standard for monitoring long-term glycaemic 
control[24] and is used to adjust therapy, assess quality of care, and predict the development of 
complications,[25] but other outcomes such as BP, body mass index (BMI), medication changes, and 
patient-reported outcomes are important. In one systematic review of information technology (IT)-
based self-management interventions,[26] only five (31.3%) of 16 studies reported on health-related 
quality of life, BP, or BMI, and only six (37.5%) of 16 studies reported on depression, whilst none 
reported on anxiety. Some large-cluster randomised, controlled trials (RCTs) have presented findings 
on quality of life and psychological well-being (i.e. depression or anxiety),[27–29] but they remain a 
minority. TH could have a positive or negative effect on health-related quality of life, health care 
utilisation, and psychological well-being.[27] The potential effects of TH on medication dosage are 
also unclear. TH-associated improvements in HbA1c could result in decreased dosages; in contrast, 
timely medication adjustments and closer supervision could result in increased dosages for tighter BG 
control. 
This study addresses some of the above limitations. It aims to examine the effects of MTH on a range 
of clinical (HbA1c, BP, daily insulin dose, diabetes outpatient appointments (DOAs)) and patient-
reported outcomes (health-related quality of life and psychological well-being). In line with the model 
of behaviour change used to guide the evaluation,[30] we hypothesised that compared to standard 
care, the MTH intervention would significantly improve HbA1c, BP, quality of life, and psychological 
well-being. We did not have a priori hypotheses on the effects of MTH on insulin dosage and DOAs, as 
increases and decreases in these outcomes could both be appropriate for better health outcomes. 
  
Research design and methods 
Eligibility and study design 
An RCT design was used to compare standard care supplemented with MTH to standard care alone. 
The study took place in a diabetes clinic in East London, United Kingdom (UK). Inclusion criteria 
iŶĐluded age ϭϴ oƌ aďoǀe, pooƌlǇ ĐoŶtƌolled tǇpe ϭ oƌ tǇpe Ϯ diaďetes ;HďAϭĐ ≥ ϳ.ϱ%Ϳ[31–33] with the 
latest HbA1c collected within the last 12 months, taking insulin, and fluency and literacy in English. 
Exclusion criteria were pƌeǀious eǆpeƌieŶĐe usiŶg MTH, ƌegulaƌ eǆteŶded tƌaǀels ;≥ϯ ǁeeksͿ outside 
the UK, home visits by a district nurse for BG monitoring and/or insulin administration, a diagnosis of 
kidney failure or sickle cell disease, pregnancy, and dexterity/visual problems compromising the use 
of a mobile-phone. We planned to recruit 248 participants to the study following a sample size 
calculation.[30] 
The MTH intervention 
Participants allocated to the intervention group were provided with the MTH equipment (BG meter, 
BP monitor, mobile-phone, and Bluetooth cradle) and training. The mobile-phone software allowed 
participants to store and transmit diabetes-related data (BG and BP readings, time since last meal, 
level of physical activity performed that day, insulin dose, and weight) to an MTH nurse (see data 
recording and transfer steps in Supplementary File 1). Participants were recommended to continue to 
follow their regular BG and BP self-monitoring routine (a minimum of one clinical reading per month 
was recommended for those not prescribed self-monitoring BP). Colour-coded graphical feedback on 
the data recorded could be accessed through the mobile-phone menu, and was automatically 
displayed following each data transfer. The MTH nurses accessed the data transmitted to the server 
via a Web portal also accessible to MTH patients. The MTH monitoring service and equipment were 
provided by a private company. In addition to providing feedback on out-of-range clinical readings (as 
needed) and education on lifestyle changes (six weekly educational calls), the MTH nurses supported 
insulin titration; if a more substantial medication review was required, participants were 
recommended to make an appointment with their diabetes specialist nurse (DSN). This minimised the 
possibility for patient emergencies to occur as a result of MTH care. A detailed intervention protocol 
has been published.[30] 
Standard care 
Standard care at the diabetes clinic consisted of follow-up appointments with a DSN every three to 
four months, and one annual or two semi-annual appointments with diabetes consultants, depending 
on glycaemic control. A DSN was available during working hours to respond to urgent patient queries. 
Measures 
The majority of outcomes presented in this paper were assessed at baseline, three months, and nine 
months (unless indicated otherwise below). The primary outcome of the study was HbA1c. This was 
measured and analysed blind to group allocation using high-performance liquid chromatography 
(reference range of 4%–6%). Participants without an HbA1c test result within two months of the 
desired measurements were invited to have an HbA1c test performed and were aware this was for 
study purposes. 
Secondary clinical outcomes included BP and daily insulin dose (both at baseline and at nine months), 
and number of DOAs attended with a DSN or consultant (over nine months). Patient-reported 
outcomes were measured with commonly used, standardised, and psychometrically sound tools. 
These included assessments of health-related quality of life using both a generic measure (Short Form 
Health Survey (SF12v2), which includes a Mental and a Physical Component Scale, abbreviated to MCS 
and PCS, respectively) and a diabetes-specific measure (Diabetes Health Profile, DHP-18; three 
subscales: Barriers to Activity, Disinhibited Eating, Psychological Distress). Symptoms of depression 
(Centre for Epidemiologic Studies Short Depression scale, CESD-10) and anxiety (Short Trait Anxiety 




This study was approved by the Joint University College London/University College London Hospitals 
(UCL/UCLH) Committees on the Ethics of Human Research, Committee Alpha (09/H0715/69). The RCT 
was registered with ClinicalTrials.gov (NCT00922376). 
Consent 
Participants with an appointment in the following two weeks were screened for eligibility and sent 
recruitment materials. Those who failed to respond or did not respond negatively were approached 
by a researcher blind to group allocation after their appointment. Participants willing to enrol in the 
study signed a consent form, and were given a baseline questionnaire to complete alone, or with the 
researcher. 
Randomisation 
Randomisation was carried out by a member of the research team upon receipt of the completed 
baseline questionnaire, and independently of DSNs, using an online sequence generator that 
generated randomised block allocations (blocks of 20). 
Follow-up assessments 
Three- and nine-month follow-up questionnaires were sent by mail to participants, and clinical data 
were collected from the medical records. 
Training 
MTH nurses received training to 1) use the equipment (demonstrations and hands-on experience), 2) 
deliver the intervention (i.e. familiarisation with intervention protocol requirements), and 3) remotely 
ĐoŶŶeĐt to aŶd Ŷaǀigate patieŶts͛ eleĐtƌoŶiĐ diaďetes ŵediĐal ƌeĐoƌds. AŶ eŶgiŶeeƌ ǀisited 
intervention participants within two weeks of randomisation to deliver the MTH devices and training 
(see details in Supplementary File 1). 
Statistical analysis 
Baseline differences between groups were examined using independent Student t tests and Chi-
Square tests. Hierarchical linear models (HLMs) were used to compare mean changes in primary and 
secondary outcomes between MTH participants and controls. Random effects accounted for within-
participant correlation, and were fitted using a first-order autoregressive covariance structure which 
assumes a steady decrease in correlations between measurements with time. Baseline differences 
were adjusted for and entered as covariates (fixed effect). A significant treatment Group by Time 
interaction was interpreted as evidence for differential treatment effectiveness. For all outcomes, we 
calculated Hedges g standardised effect sizes for mean group differences at follow-up, and 95% 
confidence intervals (CIs). A Mann-Whitney test was used for between-group comparisons on the 
number of attended DOAs. 
All analyses were conducted on an intention-to-treat (ITT) principle. For the primary outcome, HbA1c, 
a sensitivity analysis was performed that included only MTH participants with monthly data transfers 
to verify the robustness of the findings. Monthly transmissions were not a minimum protocol 
requirement, but were considered to be an indicator of regular engagement with, and receipt of, the 
MTH iŶteƌǀeŶtioŶ. Foƌ all aŶalǇses the leǀel of sigŶifiĐaŶĐe ǁas set at p < Ϭ.Ϭϱ. 
There were less than 5% of missing data. Data were missing completely at random (Little's test), 
suggesting the imputation method used was unlikely to influence results.[34] Stochastic regression 
imputation was used (using Markov Chain Monte Carlo methods) to impute data at the scale level. 
Missing primary outcome data or unreturned questionnaire data were not imputed. 
  
Results 
Several recruitment challenges (high non-attendance rates, exclusions due to poor English, 
gatekeeping by health care professionals, changes to discharge policy) were experienced and are 
reported in another paper.35 In total, 205 (70.5%) of 291 people invited to take part in the study and 
confirmed to be eligible refused to participate. Eighty-one (94.2%) of 86 enrolled participants 
ƌetuƌŶed theiƌ ďaseliŶe ƋuestioŶŶaiƌe aŶd ǁeƌe ƌaŶdoŵised to the iŶteƌǀeŶtioŶ ;Ŷ = ϰϱͿ aŶd ĐoŶtƌol 
;Ŷ = ϯϲͿ gƌoups. Figure 1 is a Consolidated Standards of Reporting Trials (CONSORT) diagram of the 
study flow.  
 
 
Figure 1. CONSORT flowchart. 
 
CONSORT: Consolidated Standards of Reporting Trials; BP: blood pressure; MTH: mobile telehealth; 
NA: not applicable; DOA: diabetes outpatient appointments. Reasons given for dropouts and loss-to-
follow-up are those reported by participants. Contract constraints refer to the agreed MTH 
monitoring date with the private company. 
Table 1 desĐƌiďes ĐhaƌaĐteƌistiĐs of the studǇ saŵple. IŶteŶsiǀe iŶsuliŶ theƌapǇ ;≥ϯ dailǇ iŶjeĐtioŶsͿ 
was prescribed to 53.1% of participants. Fourteen (17.3%) participants had a healthy weight 
;BMI < Ϯϱ kg/ŵϮͿ, the ƌeŵaiŶiŶg ǁeƌe oǀeƌǁeight ;≥ Ϯϱ kg/ŵϮ, Ŷ = Ϯϭ, Ϯϱ.ϵ%Ϳ oƌ oďese ;≥ ϯϬ kg/ŵϮ, 
Ŷ = ϰϲ, ϱϲ.ϴ%Ϳ. With the eǆĐeptioŶ of geŶdeƌ ;p = Ϭ.ϬϭϯͿ, theƌe ǁeƌe Ŷo statistiĐallǇ sigŶifiĐaŶt 
differences at baseline between groups.  
 
Table 1. Demographic and clinical characteristics of study participants at baseline. 
 
aTheƌe ǁas a sigŶifiĐaŶt diffeƌeŶĐe iŶ geŶdeƌ distƌiďutioŶ ďetǁeeŶ gƌoups ;t = ϲ.ϭϯ, p = Ϭ.ϬϭϯͿ. 
b
One eligibility criterion in our protocol was for the most recently measured HbA1c in the last 12 
ŵoŶths to ďe ≥ϳ.ϱ% at the tiŵe of ƌeĐƌuitŵeŶt. Theƌe ǁeƌe ϭϲ ;ϭϵ.ϴ%Ϳ paƌtiĐipaŶts ;fiǀe of ǁhoŵ 
were in the mobile telehealth (MTH) group) who had an HbA1c below 7.5% by the time baseline 
HbA1c was collected. To maximise sample size, these participants were not excluded from the 
analyses. Regarding blood pressure, 34 (41.9%) of the sample at baseline had a blood pressure 
greater than the threshold above which initiation or intensification of hypertensive is required 
(140/80 mmHg). 
GCSE: General Certificate of Secondary Education; HNC: higher national certificate. 
 
ITT analyses 
Table 2 presents the adjusted estimated marginal means from the HLM models for primary and 
secondary outcome measures in ITT analyses. For the primary outcome, HbA1c, there was a gradual 
0.51% mean reduction in MTH participants from baseline to nine months, compared to a mean 
increase of 0.05% in controls. The Group by Time interaction was not statistically significant and the 
effect size for group differences at follow-ups remained small, with 95% CIs crossing zero.  
 
Table 2. Changes in primary and secondary outcomes. 
 
DHP-18: Diabetes Health Profile; SF12v2: Short Form Health Survey; CESD-10: Depression scale; STAI-
6: Anxiety Scale. The DHP-18 includes three subscales on barriers to activity, disinhibited eating, and 
psychological distress. For the SF12v2 and DHP-18, scores are transformed to a 0–100 scale as per 
scoring instructions. For SF12v2, higher scores represent better quality of life; For the DHP-18, CESD-
10 and STAI-6, higher scores represent worse quality of life, and more severe symptoms of depression 
and anxiety. Consistent with other research in this area,[36] the trial start date was taken as the date 
on which mobile telehealth (MTH) equipment and training was provided to intervention participants. 
For controls, the trial start date was the return date of the completed baseline questionnaire. 
None of the Group by Time interaction effects for secondary outcomes were significant, although the 
ďoƌdeƌliŶe p ǀalues foƌ BP ;sǇstoliĐ, p = Ϭ.Ϭϱ4) and for mental health-related quality of life (SF12v2-
MCS, p = Ϭ.ϬϱϳͿ Đould iŶdiĐate a tƌeŶd iŶ faǀouƌ of MTH. The ŵeaŶ ƌeduĐtioŶ iŶ sǇstoliĐ BP fƌoŵ 
baseline to nine months in interventions was 3.2 units compared to a 5.9-unit increase for controls. 
SF12v2-MCS scores remained relatively stable in MTH participants during the nine-month 
iŶteƌǀeŶtioŶ peƌiod ;fƌoŵ ϰϳ.ϯϲ ± ϭϮ.ϯϴ to ϰϴ.ϳϰ ± ϭϮ.ϬϵͿ, Đoŵpaƌed to a ǁoƌseŶiŶg iŶ ĐoŶtƌols ;fƌoŵ 
ϰϲ.ϰϰ ± ϭϮ.ϭϭ to ϰϬ.ϲϴ ± ϭϭ.ϴϬͿ. The effeĐt size foƌ gƌoup diffeƌeŶĐes at nine months was particularly 
laƌge foƌ this outĐoŵe ;Hedges g = −Ϭ.ϲϲͿ aŶd CIs did Ŷot Đƌoss zeƌo, leŶdiŶg fuƌtheƌ suppoƌt to aŶ 
MTH effect on mental-health related quality of life. Similarly, scores on the depression scale (CESD-
10) improved over nine ŵoŶths foƌ MTH paƌtiĐipaŶts ;fƌoŵ ϵ.ϵϰ ± ϲ.ϳϭ to ϴ.ϳϱ ± ϲ.ϱϯͿ Đoŵpaƌed to a 
ǁoƌseŶiŶg foƌ ĐoŶtƌols ;fƌoŵ ϭϬ.ϴϳ ± ϲ.ϱϲ to ϭϮ.Ϯϳ ± ϲ.ϯϲͿ. Although the p ǀalue foƌ the Gƌoup ďǇ Tiŵe 
interaction was not significant, the effect size for mean group differences at nine months was large 
;Hedges g = Ϭ.ϱϯͿ ǁith CIs that did Ŷot Đƌoss zeƌo, ǁhiĐh Đould iŶdiĐate a poteŶtial effeĐt of the MTH 
intervention. 
The Group by Time interaction was not significant for daily insulin dose. There were no significant 
differences in the median number of DOAs attended during the study with DSNs by MTH participants 
;ŵediaŶ = ϭͿ aŶd ĐoŶtƌols ;ŵediaŶ = ϮͿ ;U = ϱϴϭ.ϱϬ, z = −Ϭ.ϰϳ, p = Ϭ.ϲϯϳͿ, oƌ iŶ the ŵediaŶ Ŷuŵďeƌ of 
DOAs atteŶded ǁith diaďetes ĐoŶsultaŶts ďǇ MTH paƌtiĐipaŶts ;ŵediaŶ = ϭͿ aŶd ĐoŶtƌols ;ŵediaŶ = ϭͿ 
;U = ϲϮϲ.ϬϬ, z = Ϭ.Ϭϳϯ, p = Ϭ.ϵϰϮͿ. 
Sensitivity analysis 
A sensitivity analysis carried out for the primary outcome, HbA1c, included 22 MTH participants with 
at least one monthly data transfer.30 Mean HbA1c (%) at baseline, three months, and nine months 
foƌ the ϮϮ MTH paƌtiĐipaŶts ǁeƌe ϴ.ϵϬ ± ϭ.ϰϯ, ϴ.ϳϵ ± ϭ.ϰϯ, ϴ.ϯϱ ± ϭ.ϰϯ, ƌespeĐtiǀelǇ. ‘esults ĐoŶfiƌŵed 
the ITT fiŶdiŶgs ;FϮ, ϴϬ.ϳϮ = ϭ.ϴϴ, p = Ϭ.ϭϲϬ foƌ the Group by Time interaction; Hedges g values were 
Ϭ.ϬϬ ;ϵϱ% CI −Ϭ.ϱϯ, Ϭ.ϱϯͿ at thƌee ŵoŶths aŶd Ϭ.ϯϴ ;ϵϱ% CI −Ϭ.ϭϲ, Ϭ.ϵϮͿ at ŶiŶe ŵoŶths. 
  
Discussion 
This study investigated the effects of MTH on clinical and patient-reported outcomes. Recruitment 
challenges are detailed in another paper with data on reasons for refusal, exclusions, and the 
contextual factors that hampered recruitment,[35] and the sample size underlines the need to 
interpret findings cautiously. Failure to reach the targeted sample size is not uncommon and 
happened in 45% of Health Technology Assessment and UK Medical Research Council-funded 
RCTs.[36] The majority (55%) of sample sizes in diabetes MTH studies are smaller[38] than 80, making 
this study one of the larger evaluations. 
Supplementing standard care with MTH did not result in statistically significant improvements in 
HbA1c. This lack of effect was supported in ITT and sensitivity analyses. The trends in HbA1c were, 
however, in the expected direction and a larger sample size may have yielded significant results. 
Several reviews[15,19,39] have underlined the limited evidence-base to support the widespread 
adoption of TH to achieve clinical improvements in glycaemic control, yet other work has suggested 
the opposite.[29,36,40] 
Several factors can help explain the above inconsistencies. First, the ability for the MTH nurse to make 
changes to medication dosages may vary across studies. In the current study, although the MTH nurse 
recommended appropriate insulin adjustments to MTH participants, they were asked to schedule an 
appointment with their DSN if more substantial dosage changes were required, which could also 
explain the non-significant effect of MTH on insulin dose. A similar study[41] proposed that this model 
of care may have limited the effect of MTH on HbA1c. This is also supported in a review[18] in which 
TH iŶteƌǀeŶtioŶs suppoƌtiŶg ĐhaŶges iŶ patieŶts͛ pƌesĐƌiptioŶs had a gƌeateƌ iŵpaĐt oŶ HďAϭĐ. 
Second, inconsistencies in findings across TH studies may be related to intervention content. A 
greater number of self-monitoring of BG (SMBG) elements (e.g. patient education, provider 
education, structured SMBG profile, SMBG goals, feedback, data used to modify treatment, 
interactive communication or shared decision making) has been associated with greater effectiveness 
in reducing HbA1c.[42] Future syntheses of the literature may benefit from considering these 
differences in intervention content. The application of behaviour change taxonomies to this area of 
research may help determine the most effective active ingredients in MTH studies.[43] Third, HbA1c 
is a measure of long-term glycaemic control as it reflects BG levels over the past 8–12 weeks.[25] The 
use of other indicators to measure BG control over shorter time periods (e.g. glycaemic variability, 
time in range) have been recommended[44] and may yield more consistent findings on the effects of 
MTH on diabetes control, particularly for studies with shorter intervention periods. Finally, differences 
in intervention fidelity may help explain inconsistencies in findings. Intervention fidelity data are 
rarely reported, yet those from the current study[35] revealed that the MTH intervention was 
delivered at a lower dose than intended, and this may have limited the effects of the MTH 
intervention. 
OŶlǇ appƌoǆiŵatelǇ half of ͚telediaďetes͛ studies ŵeasuƌe BP as aŶ outĐoŵe[45] and intervention 
effects are inconsistent. A meta-analysis of TH studies[18] found no significant effect on BP. In this 
study, poorly controlled hypertension was not an inclusion criterion, and 41.9% had baseline BP 
ƌeadiŶgs aďoǀe the thƌeshold to iŶitiate oƌ iŶteŶsifǇ hǇpeƌteŶsiǀe ŵediĐatioŶ ;i.e.ϭϰϬ/ϴϬ ŵŵHgͿ. This 
may have limited the magnitude of BP changes and may explain the borderline significance of the 
findings. These trends in the data are noteworthy, however, given they occurred in a study with little 
emphasis on BP. The protocol[30] required that lifestyle advice be provided only once to a patient 
above the recommended threshold, after which a visit to the doctor to adjust hypertensive 
medication was encouraged. In addition, MTH usage data showed that BP readings were infrequently 
transmitted,[30] minimising clinical intervention opportunities. Personalised feedback is believed to 
make self-monitoring of clinical readings more actionable.[4] This is the mechanism that may have 
resulted in the encouraging trends observed in BP. 
Effects sizes for mean group differences at nine months on the mental health dimension of the 
SF12v2 (0.66, CI 95% –1.14 to 0.18) and CESD-10 Depression Scale (0.53, CI 95% 0.06–1.01) were 
large and in favour of MTH, with CIs not crossing zero. Scores on these measures deteriorated over 
time for controls whilst remaining more stable in MTH participants. Although the study was not 
primarily designed to examine these effects, the patterns observed could be indicative of a protective 
effect of MTH on mental health, possibly through the social support received through MTH contacts. 
Evaluations of TH interventions that do not focus on social support often do not measure it, but 
qualitative interviews following teleconsultations have suggested TH may increase perceived social 
support.[46] This may be an added advantage of TH that future studies would benefit from examining. 
There have been some concerns about the potentially detrimental effects of TH. TH may increase the 
burden of illness work or isolate patients, by decreasing face-to-face contacts with health care 
pƌoǀideƌs, oƌ ŵaǇ uŶdeƌŵiŶe aŶ iŶdiǀidual͛s ĐhoiĐe aŶd iŶdepeŶdeŶĐe.[47,48] In light of these 
concerns, the lack of effects of the tested intervention on the physical dimension of health-related 
quality of life (SF12v2-PCS) and on diabetes-specific quality of life (DHP-18), or on measures of 
depression and anxiety, can be considered reassuring. The omission of psychological variables from 
TH evaluations has been critiqued[23,27] and our data add to this small body of evidence in this area. 
Overall these findings are in line with other work reporting on quality of life or psychological well-
being.[20,27,29,49] A review of psychological, self-management and educational interventions in 
diabetes50 underlined the need for interventions to clearly address negative mood for improvements 
in psychological well-being, which was not the case in this study. 
Similar to another study,[28] MTH was not found to influence the number of DOAs attended at the 
clinic. Studies on TH for diabetes have often focused on measures of hospitalisation or inpatient 
stays.[51–53] Fewer studies have measured outpatient visits. In those that have, TH has generally 
been associated with increases in outpatient visits.[52,53] As in our study, these studies required 
patients to visit their regular diabetes provider for medication reviews. They recruited participants at 
risk of or frequently using inpatient and emergency services, however, and facilitated appointment 
scheduling for intervention participants, both of which may have influenced the findings. In contrast, 
another study[51] in which TH care coordinators facilitated scheduling of outpatient visits found that 
their number was significantly reduced in intervention participants compared to controls. These 
conflicting findings suggest that in some studies, TH may result in appointments that prevent further 
health deterioration, whilst in other studies TH may prevent health problems from occurring 
altogether. A range of factors including patient and disease characteristics, service use before TH, the 
TH monitoring protocol and model of care, as well as the compensation model for health providers, 
are likely to influence findings on outpatient appointments. 
This study is not without limitations. It is a comprehensive evaluation that relies on a range of 
psychometrically valid tools. Failure to reach the targeted sample size is the most notable drawback, 
particularly given the number of outcomes measured. As mentioned above, however, this is not 
uncommon in this area of research and it is important for clinical evaluations to include patient-
reported outcomes too. As a result, these findings need to be interpreted with caution. The low 
response rate limits the generalisability of the findings,[54] although importantly refusal reasons do 
not differ from other studies, including those with a higher participation rate.[]35] It may be more 
appropriate to consider the analyses conducted as exploratory. Also, the focus on DOAs with DSNs 
and consultants working at the clinic was based on the data available. MTH participants may have 
visited their general practitioner to discuss their diabetes. This is unlikely, however, as patients are 
referred to their DSN by their general practitioner for diabetes-related care. Finally, this study did not 
examine the relationship between MTH usage data and treatment effectiveness. Results of the 
sensitivity analysis suggest that there is little relationship between variations in MTH usage and 
HbA1c, but research studies with larger sample sizes allowing for multiple testing may benefit from 
considering the moderating effect of MTH usage on outcomes. 
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